
    
      Randomized crossover clinical trial about the impact of a telemedicine program (Emminens
      Conecta® System, Roche Diagnostics SL) vs. the conventional medical follow-face of 18 months
      for the care of patients with DM1 intensive treatment with CSII (Accu-Chek Spirit®, Roche
      SL).

      Two groups: one group with interactive clinical monitoring through a telemedicine platform
      (TM) and other conventional medical follow-up group (SMC) during 6 months. Being a crossover
      trial, both groups passing through both conditions (TM and SMC) during 6 months.
    
  